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Abstract 
Background 
Giardia lamblia is a common cause of waterborne disease. It is endemic in many 
parts of the world, especially where sanitation is poor, but in Europe and North 
America it is most often encountered in outbreaks following contamination of 
drinking water. The first registered outbreak of giardiasis affecting a large community 
in Norway happened in Bergen in the autumn of 2004. The reservoir “Svartediket” 
was the source, and the water probably held Giardia cysts for several weeks.  
Giardia can cause acute and chronic gastroenteritis. Several drugs constitute effective 
treatment, and metronidazole is the main drug available in Norway. Prior to the 
outbreak in Bergen there were no published studies on long term effects after 
eradication of the parasite.  
Aims 
The aim of the studies in this thesis is to investigate the course of giardiasis and its 
consequences following a large outbreak in an area where Giardia is not endemic. 
Methods 
In the first study, we concentrated on patients from general practice. Patients with 
clinically defined giardiasis were identified through a search in the medical records at 
two general practice clinics located in the area receiving water from the contaminated 
reservoir. Of the 7,100 persons registered, 134 fulfilled the inclusion criteria and 119 
consented to take part in the study. Data were retrospectively obtained from the 
medical records. The patients were then requested to complete a mailed questionnaire 
and submit stool samples six months after the outbreak. A second questionnaire was 
sent out one year after the outbreak. The main outcome variable was abdominal 
symptoms that were not present prior to the acute infection. 
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In the second study, we investigated a historic cohort of 1252 patients with giardiasis 
verified by detection of Giardia in stool samples submitted as part of regular clinical 
investigations in Bergen during the outbreak. A 2:1 control group matched by age and 
gender was recruited from the general population of Bergen. This group was later 
expanded so that the whole control group consisted of 3594 individuals. All 
participants received a questionnaire by mail three years after the outbreak. Main 
outcome variables were irritable bowel syndrome (IBS) according to Rome III criteria 
and “chronic fatigue” as defined by the Fatigue Questionnaire. 
Results 
In the group of patients from general practice the majority was between 20 and 39 
years of age (51.4%), and there were more women (69.3%) than men. The diagnosis 
was supported by a positive test for Giardia lamblia in 55% (66/119) of the patients. 
Treatment with metronidazole was given to 89 (75%), and after initial treatment 36% 
(32/89) returned to their doctor because symptoms recurred. A second prescription 
was given to 28% (25/89), after which 16% (14/89) returned once more. 11% (10/89) 
received a third treatment with metronidazole. Six months after the outbreak stool 
samples were positive for Giardia in three of 82 patients. At this point 37% (44/118) 
reported gastrointestinal symptoms related to their Giardia-infection, and after 12 
months this proportion was 19% (19/99). 
In the cohort of patients with laboratory verified giardiasis the prevalence of IBS 
three years after the outbreak was 46% (355/770), compared to 14% in the control 
group. The adjusted relative risk (RR) was 3.4 (95% confidence interval (CI) 2.9 to 
3.8). The prevalence of chronic fatigue was 46% (366/794) among the Giardia-
patients, and 12% among the controls, giving an adjusted RR of 4.0 (95% CI 3.5 to 
4.5).  IBS and chronic fatigue were associated, but there was also an increased risk of 
having IBS only (RR 1.8, 95% CI 1.4 to 2.3) or chronic fatigue only (RR 2.2, 95% CI 
1.7 to 2.8).  
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Discussion  
In the study from general practice we identified patients that would have been missed 
by a strict laboratory based inclusion criterion, either because stool samples were not 
submitted or due do misclassification when samples were negative. Several patients 
did not receive treatment and this could suggest that they did not have giardiasis, but 
another reason could be that they called at the medical centre before the outbreak was 
known and recovered spontaneously without treatment.  After clearance of the 
parasite a substantial proportion of the patients had persisting symptoms 6 and 12 
months after the outbreak, which shows that potential negative health effects of 
giardiasis was more extensive than first anticipated. 
In the cohort of persons with verified giardiasis the infection was associated with a 
high prevalence of IBS and chronic fatigue three years after the outbreak, and the risk 
was significantly higher than in the control group. This supports the findings in the 
group from general practice, and shows the consequences in a larger population and 
over a longer period of time. The prevalence of IBS in this study and gastrointestinal 
symptoms in the first one differs, but cannot be easily compared. The sample sizes 
vary, the case definitions are different and the questionnaires used to define the 
outcomes are not the same. Put together the two studies illustrate a wider range of the 
clinical consequences after the outbreak. 
Conclusions 
These studies show that a considerable proportion of patients consistently had 
persisting symptoms after giardiasis from the time of the acute infection and up to 
three years after.  The association between acute giardiasis and later gastrointestinal 
symptoms and fatigue is strong. This calls for more research on the mechanisms for 
both giardiasis and medically unexplained physical symptoms like IBS and chronic 
fatigue.  
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1. Background 
1.1 Giardia lamblia 
1.1.1 History and nomenclature 
Giardia lamblia has been considered one of the most ancient and primitive eukaryotic 
organisms on the planet(2). This view has been challenged by resent research(3), but 
still this parasite has been around for a long time, and most of it without our 
awareness. Our knowledge about microorganisms was very limited up to the second 
half of the 19th century when a range of bacteria and other microbiological pathogens 
were described and linked to specific infections. However, as early as in 1681 the 
Dutch pioneer microscopist Antony van Leeuwenhoek observed a small animalcule in 
great numbers in his own diarrhoeal stools. Based on his notes and drawings it has 
been concluded that this was Giardia lamblia(4). The Czech physician Vilém D. 
Lambl described it in more detail in 1859, calling it Cercomonas intestinalis(5), and 
in 1888 Blanchard named it Lamblia intestinalis in his honour(2). In the same period 
other organisms later known to have been Giardia species were described. The name 
Giardia, given in honour of the French zoologist Alfred M. Giard(2), was used for the 
first time by Kunstler in 1882 for an organism he found in tadpoles. In 1915 Kofoid 
and Christensen proposed Giardia for the genus and lamblia for the species(2), and 
this is still the official name according to the Integrated Taxonomic Information 
System(6). 
Giardia lamblia is the most common name in English literature, but G. intestinalis 
and G. duodenalis are also used and some argue that the latter is the most correct 
form(7). So far there is no agreement to choose one before the others. In medical 
literature the term “Giardia” is often used synonymously with the species G. lamblia. 
 14 
1.1.2 Microbiology 
G. lamblia is a unicellular flagellated motile eukaryotic microorganism. Other 
Giardia species include G. agilis found in amphibians and G. muris found in rodents, 
but G. lamblia is the only one found in man. Within the species G. lamblia there are 
several genotypes dividing it into different “assemblages”, each with preference to 
different hosts and with possible variations in the clinical manifestations of infection. 
Assemblages A and B are found in humans. The range of variations has led to the 
argument for a revision of the whole Giardia taxonomy(7). 
G. lamblia is found in two distinct forms, the cyst and the trophozoite. In the 
environment it survives as cysts, which to a certain extent is resistant to 
environmental stress. However, they will not survive cold winters in water(8) or 
deposited in soil(9). The cyst has a relatively robust wall consisting of 60% 
carbohydrates and 40% proteins with strong interactions between them(3). Inside the 
cyst wall electron microscopy has revealed the existence of four nuclei, ribbon-like 
microtubules and flagella(10). After ingestion the cyst undergoes rapid transformation 
into the trophozoite stage within 15 minutes. This excystation is triggered by the acids 
in the stomach, and after passing into the small intestine the cysts rupture and release 
the excyzoite, an intermediate form of the parasite. The excyzoite then divides twice 
producing four trophozoites(11).  
The trophozoite is the form that causes disease in man. It has a characteristic 
appearance with a pear-shaped outline, four pairs of flagella and two nuclei 
symmetric to the long axis. A ventral disc is located on the concave side of the body 
(Figure 1). Giardia differs from other eukaryotes by the absence of peroxisomes and 
proper mitochondria, but contains mitochondria-like organelles called mitosomes(12). 
The trophozoites colonize the small intestine of their host, predominately in the mid-
jejunum, where they attach to the intestinal wall by their ventral disk(2). They 
multiply by cell division, but genomic and population genetic studies have shown 
evidence of heterozygotes indicating some kind of recombination or sexual 
reproduction as well(13-15). Some trophozoites encyst following nuclear replication. 
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This occurs in the jejunum, and is triggered by host factors like high levels of bile, 
low levels of cholesterol and a basic pH(16). 
 
Figure 1. Giardia lamblia 
1.1.3 Clinical features of giardiasis. 
The role of Giardia in disease was unknown for centuries, well into the 20th century. 
Its ability to produce enteritis in man was suspected, but not established(17). When 
the microbiologist Clifford Dobell in 1919 convincingly argued that van 
Leeuwenhoek had been the first to identify the parasite, he made a point of 
congratulating the Dutch for not making the wrongful assumption that Giardia was 
the cause of his diarrhoea(4). In the 1950’s experimental studies showed that 
ingestion of Giardia cysts in capsules or drinking water led to infection in man, in the 
sense that cysts would later be found in stool samples. Still it could not be established 
that this caused clinical illness(18, 19). Clinical accounts suggested that the infection 
may be followed by diarrhoea and other symptoms, but there was substantial 
controversy about the pathogenicity of Giardia, as summarized by Petersen in 
1972(20). The main question was whether the parasite would cause disease, or merely 
be observed in greater numbers because the diarrhoea would constitute a more 
favourable environment in which Giardia would multiply. During the last 40 years 
Giardia has been isolated in several outbreaks of gastroenteritis in both Europe and 
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North America(21-28) providing arguments for its pathogenic potential. The 
experiment that formally established the pathogenicity of Giardia in humans by 
fulfilling the Koch postulates was published by Nash in 1987(29). Following 
thorough medical investigation 15 healthy volunteers, all men, were given sterile 
inocula with Giardia trophozoites that had been grown from two different strains 
(GS/M and Isr) of cysts obtained from patients suffering from giardiasis. The 
trophozoites were administered by a tube into the small intestine. Later cysts would be 
detected in multiple stool samples from all ten men receiving GS/M Giardia, as sign 
of infection. Giardia cysts were not detected in any of the five men receiving the Isr 
strain. Of the ten men infected with Giardia four developed typical diarrhoeal disease, 
which proved that Giardia can lead to both infection and clinical disease. 
The disease caused by G. lamblia is called giardiasis (or lambliasis/lambliosis). It 
presents as acute or chronic gastroenteritis, and the clinical manifestations will vary 
from hardly any symptoms at all to profuse diarrhoea accompanied by severe weight 
loss and fatigue(30). Both experimental and clinical studies have shown that people 
may be infected without developing symptomatic giardiasis(18, 22, 29). 
The mechanisms by which Giardia causes disease are not fully understood. The 
diarrhoea frequently observed in symptomatic giardiasis is caused by combined 
malabsorption and hypersecretion that is the result of diffuse shortening of microvilli. 
These alterations are partly mediated by host T lymphocytes that are activated 
secondary to disruption of epithelial tight junctions and increased transepithelial 
permeability(31). Most of this knowledge is based on studies in vitro and in animals, 
but in 2007 Troeger and co-workers described epithelial barrier dysfunction and signs 
of both malabsorption and hypersecretion in biopsies from the distal duodenum of 13 
patients with chronic giardiasis(32). 
Acute giardiasis is characterized by diarrhoea, abdominal cramps, flatulence, foul-
smelling stools, bloating, nausea, anorexia, weight loss and fatigue(27, 29, 33). The 
incubation period is just over one week in experimental studies(29, 34), but may be 
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longer in clinical settings(35-37). Most patients will be treated in the community but 
an unknown proportion of patients will need hospital care (38). 
Some patients will recover spontaneously, and it has been suggested that this will 
happen in 2 to 6 weeks(30, 39). However, there are no good data on the proportion of 
patients that will recover without treatment, nor on how long spontaneous recovery 
may take. This issue is further complicated since different strains of Giardia will have 
different pathogenic properties(29), and also because host factors may play a role. 
van Leeuwenhoek is credited with the first description of Giardia, but he may also 
have given the first description of chronic giardiasis. He found the “animalcules” in 
great numbers in his stools when loose, but very few or none when the stools were 
normal. He wrote of his experience from the summer of 1681: "I have usually of a 
morning a well-formed stool; but hitherto I have had sometimes a looseness of the 
bowels in two, three, or four weeks, so that I went to stool some twice, thrice, or four 
times a day. But this summer this befell me very often, and especially when I took hot 
smoked beef, that was a bit fat, or bacon, which food I eat with much enjoyment; 
indeed, it persisted once for three days, and whatever food I took I retained in my 
body not much above four hours . .”(4). 
In some patients chronic giardiasis may persist for months and even years if left 
untreated. Features of chronic giardiasis are intermittent diarrhoea with malabsorption 
resulting in weight loss, fatigue and possibly vitamin deficiencies (30, 40). The 
symptoms of chronic giardiasis will often resemble and be indistinguishable from 
irritable bowel syndrome (IBS)(41, 42).  
Chronic or repeated infections in children may cause failure to thrive, reduced weight 
gain and impaired cognitive development(43, 44), which is of great concern in 
regions where sanitation is poor and Giardia endemic. 
There is limited knowledge on persisting symptoms and complications of giardiasis 
after eradication of the parasite. Prior to the outbreak in Bergen in 2004 there were no 
published studies on this topic.  
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1.1.4 Treatment 
Several drugs are effective against Giardia, but there is uncertainty about the optimal 
regimen(45, 46). There is concern about the development of resistance to existing 
treatment, and research on new therapeutic drugs for giardiasis has been initiated(46). 
In Norway metronidazole is the only drug approved for treatment of giardiasis, and 
for refractory cases alternative drugs must be imported(47). In treatment schedules 
with metronidazole given twice or thrice daily for five to ten days the efficacy ranges 
from 60 to 100% (median 89%)(45). Shorter courses would be favourable because of 
side-effects, but are less efficacious. 
1.1.5 Epidemiology 
Giardia is mainly spread through contaminated drinking water, but other pathways of 
transmission are also recognised. The first food-borne cases were reported in 1981, 
when cysts were detected in home-prepared salmon(48). Later other outbreaks have 
been linked to noodle salad(49), fruit salad(50) and raw sliced vegetables(51). In the 
1980’s records of two outbreaks of giardiasis caused by fecal contamination of 
swimming pools were published(52, 53). A review of all known outbreaks associated 
with recreational waters in the United States between 1971 and 2000 concluded that 
in 97 of 259 registered outbreaks (37.5%) protozoa were the etiologic agent(54). 
Giardiasis has also been to linked to interactive water fountains, the first report came 
from Florida in 2006(55). In 2003, 30 primary cases of giardiasis during a large 
outbreak in Boston, Massachusetts, were linked to exposure to a children’s pool, but 
as many as 105 secondary cases probably resulted from person-to-person spread(56). 
Transmission from person to person is a well-known problem in child day care 
centres(57-62), and this was the site for the first outbreak of giardiasis in Norway, in 
Trondheim in 2006(63). Not only the children are at risk, one study showed that 
nappy handling was associated with a four-fold increased risk of giardiasis(64). 
Giardia may also spread through sexual activity, and increased prevalence among 
homosexual men has been reported(65-70).  
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Giardia is widespread throughout the world. It is endemic in tropical and subtropical 
areas where hygienic conditions are poor. The prevalence of infection or symptomatic 
disease is not well established. The World Health Organization (WHO) has given the 
highest estimate to date in a 1996 report, stating that 200 million people in Asia, 
Africa and Latin America had symptoms of giardiasis(71). Numbers frequently 
quoted in review articles are prevalence rates of 2-5% in the industrialised world and 
20-30% in low-income countries(30, 72, 73). None of these estimates are backed with 
strong evidence. 
Studies on prevalence of Giardia in Europe and North America are few and yield 
diverging results. In 1972-73 the prevalence of Giardia in Colorado was 3% based on 
a laboratory survey(74). In contrast, the annual incidence rate of Giardia-infection in 
Vermont between 1983 and 1986 was 46 cases pr. 100,000 population. The incidence 
was highest among children 1-4 years of age(75). A prevalence study in five Berlin 
kindergartens in 2006 identified Giardia in three of 202 children (1.5%)(76). A meta-
analysis on 13 non-heterogeneous studies from the Nordic countries published before 
2004 estimated a pooled prevalence of 5.8% among persons with and 3.0% among 
persons without gastrointestinal symptoms(77).   
The high estimates for prevalence of Giardia infection in low-income countries are 
most uncertain. They are partly based on studies with few participants, restricted to 
patients with gastroenteritis or limited to children. In some instances there is no clear 
distinction between symptomatic or asymptomatic infection. As a result the reported 
prevalence varies.  
Several studies from South and Central America have estimated prevalence in groups 
of children. Farthing followed a group of 45 children in rural Guatemala with stool 
examination every week for three years between 1964 and 1966. All children had at 
least one episode of Giardia positive stools, and the overall prevalence was 20.2%. 
The ratio between symptomatic and asymptomatic cyst excretion varied between 1:2 
and 1:3(43). Forty years later Cook reported a prevalence of 10.9% in a larger study 
based on single stool samples from children aged 5-15 years visiting for routine 
 20 
investigation in another part of rural Guatemala. In total there were samples obtained 
from 5,705 visits during a period of four years(78). In a group of 845 children from 
marginal urban districts in Peru Giardia was found in 23.8% (79). In North-east 
Brazil one study on children followed from birth and up to the age of four years 
(mean follow-up 543 days) found a prevalence of Giardia infection of 22.8% (80). 
Another study from a different city reported detection of Giardia cysts in single stool 
samples from 13.7% of 694 pre-school children undergoing routine investigation (81). 
In Southern Brazil a similar result has been reported, a prevalence of 19.2% was 
found in 133 children in two day care centres(82). All the referred studies are 
restricted to children. A population based study on 2,367 individuals of all age groups 
from three different municipalities in southern Brazil revealed a prevalence of only 
1.7%(83).   
Giardiasis is also common in Africa. In a study from the rural Nile delta of Egypt 
stools were analysed once a week as part of a six months investigation of 42 children, 
and during this period Giardia was detected in 41 of the children and in 42% of the 
specimens analysed(84). In rural Ethiopia a prevalence of 25.8% among children was 
recorded in the dry season of 2005 and 39.8% in the wet season of 2006(85). A 
Zambian study on 100 pre-school children followed for one year with analyses of 
stool samples once a month showed that 75 of the children had been infected with 
Giardia during that year, but 21 of those had no episodes of diarrhoeal disease(86). 
From Africa there are also some studies where children with diarrhoeal disease are 
included. Among 31 Gambian children with diarrhoea and malnutrition giardiasis was 
diagnosed in 14 (45%)(87). A larger study from a district hospital in Mozambique 
found that only 2.5% of 529 children with diarrhoea were infected with Giardia(88), 
and similarly Moyo found Giardia in 1.9% of 280 children hospitalised with 
diarrhoea in Tanzania(89).  
A review of 33 articles on giardiasis in South Asia, South East Asia and the Far East 
in the period 2002-2007 revealed that the prevalence of Giardia varied markedly 
between regions and different demographic groups. The prevalence ranged from 
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around 3% in several South East Asian regions to 23% in the Kathmandu valley, and 
as high as 73% in Eastern parts of Nepal(90).  
Exposure to Giardia is common and infection frequent in many areas, but it is 
challenging to estimate the consequences of giardiasis in developing countries. This is 
emphasised by the findings in a study from Dhaka, Bangladesh (91). Giardia was 
detected in 205 of 3,646 patients (5.6%) seeking treatment for diarrhoea, but also in 
440 of 2,575 controls (17.1%) without diarrhoeal illness in the previous three months. 
This inverse correlation between infection with Giardia and diarrhoeal disease was 
surprising, but indicates a more complex role of parasitic infection in endemic areas. 
The aforementioned reports on children with diarrhoea in Mozambique and Tanzania 
showed very low rates of Giardia infection (2.5% and 1.9%), but without a control 
group it is difficult to interpret the result(88, 89). A study from the Iraqi city of Dohuk 
also indicated an inverse trend. Giardia was detected in 31.3% (134/428) of children 
with diarrhoea at the local paediatric hospital, but also in 42.8% (305/712) of stool 
samples collected routinely from children in school and day care centres (134). 
It is difficult to reach a conclusion on the health impact of Giardia around the world. 
Nevertheless, diarrhoeal disease as a whole represents a major health problem and is 
still the second leading cause of death among children under five globally(92). This 
will have important implications for the management of giardiasis alongside other 
gastrointestinal infections, and Giardia was included in WHO’s “Neglected Diseases 
Initiative” in 2004(93). Giardiasis is not among the 17 listed Neglected Tropical 
Diseases the WHO has decided to focus on(94), but still receives attention (personal 
communication, Dr. Antonio Montresor, WHO). Another department of the WHO, 
the Department of Water and Sanitation Health specifically addresses the aspects of 
giardiasis linked to drinking-water(95) and safe recreational water(96). 
In developed countries the highest numbers of patients with giardiasis is found in 
outbreaks of waterborne gastroenteritis. In the period 1954 to 2001 there were at least 
132 waterborne outbreaks of giardiasis registered in Europe and North America, 104 
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of them were associated with contaminated or presumably contaminated drinking 
water(97).  
Non-epidemic cases of giardiasis in high-income countries have often been the result 
of infection abroad. In the 1970’s there were several reports on giardiasis among 
travellers to the Soviet Union(35, 36, 98, 99), and there was also one report of an 
outbreak among travellers on a Mediterranean cruise in 1973(100). Later case-control 
studies have also showed that foreign travel is associated with an increased risk of 
giardiasis(101-103), but now most patients get infected in South-central Asia and 
South America(104). A case-control study on sporadic giardiasis in England after 
excluding cases infected abroad and possible secondary cases showed that drinking 
tap water (dose-response relationship), swimming in pools or fresh water, and eating 
lettuce was associated with infection(105). 
The outbreak of giardiasis in Bergen in 2004 was the first large outbreak in Norway, 
but two outbreaks had been reported earlier in Scandinavia, both in Sweden. In 
October 1982 sewage entered the water system of the village Mjövik, and 454 of 
about 600 inhabitants (76%) fell ill with gastroenteritis. Giardia was detected in 
stools from 56 patients(26). Four years later, during Christmas of 1986, sewage 
overflow into the drinking water system exposed about 3,000 persons to contaminated 
water at the ski resort of Sälen. A total of 1,400 had giardiasis diagnosed by 
microscopy(106). The first known outbreak in Finland occured in 2007, after the 
municipal drinking water system of Nokia, a city of 30,500 inhabitants, was 
contaminated by sewer. During a 16 weeks period following the contamination the 
hospital laboratory detected Giardia infection in 97 patients(28). 
The first report on giardiasis in Norway was given in 1931, and based on figures from 
hospitalised patients without gastro-intestinal symptoms the prevalence of giardiasis 
in the healthy population was estimated to be 7% in 1941(107). In 1953 attention was 
drawn to the disease by the publication of a case report in the Journal of the 
Norwegian Medical Association(108). In a study on patients with gastrointestinal 
complaints referred to Ullevål hospital in Oslo in the period 1966-1970 Giardia was 
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found in duodenal content from 6.5% (19/293) of the patients. Giardia cysts was also 
detected in stool samples from 3.2% (6/190) of unselected hospitalised patients(20). 
The first known community outbreak of giardiasis in Norway took place in a child 
day care centre in Trondheim during the winter of 2004, in which Giardia cysts were 
detected in stool samples from 12 individuals(63). 
The annual incidence of reported giardiasis in Norway has varied between 200 and 
400 cases, with less than 100 patients infected in Norway (Table 1). The unusual high 
number in 2004 was the result of the outbreak in Bergen, which constitutes the basis 
for this thesis. Just one year prior to the outbreak, some authors questioned whether 
giardiasis is underdiagnosed in Norway(109). This concern was supported by findings 
during an investigation of raw waters in Norway in 1998 and 1999. Giardia cysts 
were found in 11.8% (48/408) of samples and 18.4% (27/147) of sites examined(110).  
 
Table 1. Reported cases of giardiasis in Norway 1992-2010(111). 
Place of 
infection 
1992 1994 1996 1998 2000 2002 2003 2004 2005 2006 2010 
Norway* 71 72 41 53 56 67 68 1327 220 98 57 
Abroad 159 178 162 328 287 349 254 253 208 196 205 
Total 230 250 203 381 343 416 322 1580 428 294 262 
*Including unknown place of infection. 
1.2 Waterborne outbreaks of disease 
The WHO states that “access to safe drinking-water is essential to health, a basic 
human right and a component of effective policy for health protection”(95). This is 
based on the experience from lessons learned. 
The plague of cholera in the early 19th century, and John Snow’s conclusion that the 
disease must have been spread by drinking water, subsequently leading to the removal 
of the handle of the water pump on London’s Broad Street, is often used as a prelude 
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to the importance of both water sanitation and the academic field of epidemiology. 
Although some aspects of the myth have been questioned, there is still unequivocal 
support for Snow’s prominent place in medical history(112), and the intriguing story 
is worthy of a novel(113). 
Sanitation has improved in high-income countries, but contamination of water still 
occurs. The focus on safe drinking water has led to surveillance programmes in 
several countries. In the US data has been collected on the occurrence and causes of 
waterborne outbreaks of disease since 1920, and has been reported periodically since 
1971. For the period 1971-2006 a total of 833 outbreaks were reported, 780 (93.6%) 
of these were associated with contamination of drinking water (114). An etiologic 
agent was identified in 467 (56.1%) outbreaks, most frequently parasites (153 
outbreaks (18.4%)). Giardia was the sole pathogen responsible for the highest 
number of outbreaks (123 (14.8%)), and linked to 28,127 cases of infection. Other 
identified microorganisms were Cryptosporidium, Shigella, Salmonella, 
Campylobacter and E. coli. The largest registered outbreak was caused by 
Cryptosporidium hominis, and happened in Milwaukee, Wisconsin in 1993. 
Retrospectively it has been estimated that 403,000 people were ill(115), 4,400 
patients were hospitalized(116), and that 50 deaths were associated with the 
outbreak(117).  
In Canada 288 outbreaks of disease in the period 1974-2001were linked to drinking 
water. Giardia was the most frequently reported causative pathogen, found in 51 of 
the 144 outbreaks where an etiologic agent was identified. The most widely known 
outbreak occurred in Walkerton, Ontario, in May 2000(118). Following heavy rain 
fall the municipal drinking water was contaminated with both Campylobacter and E. 
coli. The town’s inhabitants have been followed with regular medical examinations 
since 2002, resulting in several research projects(119, 120). 
Also in Europe drinking water may constitute a health hazard. In the period 1992-
2003 89 outbreaks were reported in England and Wales. Giardia was identified in 
only five outbreaks, and in three of these in combination with Cryptosporidium. 
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Cryptosporidium is a major concern in the UK as it alone or combined with other 
pathogens was implicated in 67 (78%) of the outbreaks(121). 
In 2007 Karanis published a review of 325 reported water-associated outbreaks 
(drinking water, recreational water, travel) of parasitic disease worldwide(97). Most 
outbreaks, 171 (52.6%), were reported in the US, while Europe accounted for 106 
(32.6%). The rest were divided between Canada, Japan, Australia and New Zealand. 
Giardia was identified as the causative agent in 130 outbreaks (40.0%) and 
Cryptosporidium in 165 (50.8%). Of the Giardia outbreaks, 104 (80%) were caused 
by contaminated drinking water compared to 77 (47%) of the Cryptosporidium 
outbreaks.  
Norway is not exempted from the threat of waterborne disease, as the Bergen-
outbreak of giardiasis in 2004 convincingly illustrates. A recent study describes the 
situation, summarising 102 waterborne outbreaks and 17,200 cases of disease in 
Norway during the period 1987-2007. An etiologic agent was identified in 60 (59%) 
outbreaks, but in contrast to the observations in the US and Great Britain parasites 
were registered in only two outbreaks. The most prevalent pathogens were 
Campylobacter (26 outbreaks (25%)) and Norovirus (19 outbreaks (19%)).The mean 
number of persons affected in surface water outbreaks was 253, the median 35(122). 
1.3 Postinfectious complications 
Infections can cause permanent injury and evident sequelae. However, in some cases 
patients experience loss of function and persisting symptoms that are difficult to 
define and without explanatory objective findings. Two conditions that are often 
investigated are irritable bowel syndrome (IBS) and chronic fatigue syndrome (CFS). 
Both are linked to infections, but are also found in patients without a history of 
preceding infectious disease. 
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1.3.1 Irritable bowel syndrome 
IBS is a common gastrointestinal disorder, both in the general population and in 
patients seen in clinical practice. The reported prevalence varies between 2.5% and 
37%, reflecting differences in settings and diagnostic criteria(123). The Rome process 
aims to reach consensus on criteria for functional gastrointestinal disorders and 
develop valid questionnaires to use in research and clinical practice. The criteria have 
been revised on four occasions, last in 2006 (Rome III)(124).  
Diagnosis of IBS is based on the presence of abdominal pain or discomfort for a 
defined period of time and linked to alterations in bowel habits(125). The practical 
use of the agreed criteria still faces obstacles, as illustrated by a study comparing 
Rome II criteria and the clinical judgement of Norwegian general practitioners 
(GPs)(126). There was poor agreement, both in overall prevalence of IBS and in 
which patients that were identified. Reasons might be that the GPs also emphasised 
psychosocial factors and that in clinical practice others symptoms, for instance 
bloating and loose stools, are often considered essential parts of the syndrome. As a 
result IBS will be diagnosed more often in patients with co-morbidity, and less often 
in patients with few symptoms restricted to the alimentary tract. 
Increased incidence of IBS has been documented after bacterial gastroenteritis caused 
by Salmonella(127, 128), Shigella(129, 130) Campylobacter(131, 132) and mixed 
Campylobacter/E. coli O157:H7(133), as well as after infection with the roundworm 
Trichinella(134). In one study on IBS following viral gastroenteritis, probably 
Norovirus-infection, 23% reported IBS after 3 months, but after 6 months the 
prevalence was no higher than in the control group (135). In a study on hospitalised 
patients in the UK there was a higher incidence of IBS after gastrointestinal (GI) 
infections, but unexpectedly also after non-GI infections compared to controls 
without infection(136). This study was small and the findings should be confirmed in 
other studies, but it reflects that mechanisms for IBS are complex. 
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One study found clinical and histological differences between patients with 
postinfectious IBS (PI-IBS) and IBS without history of precipitating infection(137). 
This suggests that PI-IBS is a clinically distinct subgroup of IBS. 
Several factors have been associated with an increased risk for PI-IBS, both pathogen 
and patient characteristics(138). In one study the toxicity of the strain was a risk 
factor for IBS six months after infection with Campylobacter(132). Prolonged 
duration of the acute illness in bacterial gastroenteritis plays a role(129, 139), but it is 
not clear whether this is a proxy for bacterial toxicity or patient vulnerability. 
Receiving antibiotic therapy for Salmonella infection was associated with increased 
risk of IBS in an observational study(140). However, since there was no control group 
interpretation is difficult. Smoking was found to be a risk factor for PI-IBS in one 
study, but few participants (18 with IBS among a total of 127) and  lack of obvious 
mechanisms for the role of smoking make conclusions uncertain(141).  The 
biopsychosocial model is considered helpful in the understanding of IBS(142), and 
different psychosocial factors have been investigated in a few studies on PI-IBS. 
Depression(131), hypochondriasis and adverse life events (143) have been shown to 
be independently associated with IBS in multivariate analyses. Patients with bacterial 
dysentery who developed PI-IBS scored higher on anxiety, depression, somatization 
and neuroticism than did controls in another study(144).  
IBS is more common among women with a reported female:male ratio up to 2.5. The 
association is stronger in clinical studies than in population based studies, and 
stronger in the Western countries compared to Asia(145). This suggests that both 
health care seeking behaviour and cultural differences may confound the results. In 
studies on PI-IBS there are conflicting results on the role of gender, but it seems like 
the impact of gender is smaller. Following the Walkerton outbreak in 2000 (mixed 
Campylobacter/E. Coli) a large number of patients developed IBS and the OR for 
female gender was 1.5 (95% CI 1.1 – 1.9)(133). Some other studies have 
demonstrated a higher incidence in women(127, 139), but others have not. No gender 
difference in development of IBS was found among patients with Shigella infection in 
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China(129)or traveller’s diarrhoea in Israel(146), or after outbreaks of Salmonella 
infection in Spain(128) and Shigella infection in Korea(130).  
1.3.2 Chronic fatigue 
Fatigue is a common feature of different diseases such as cancer, infections, 
hypothyroidism, marked anaemia and psychiatric disorders. It is an unspecific 
symptom, and most often there is little focus on fatigue in the acute phase. As a 
symptom in prolonged loss of function after apparent recovery it occupies a more 
prominent place. It is the key symptom in chronic fatigue syndrome (CFS) which 
during the last years has received more attention as it affects people of young age and 
in many cases causes profound loss of function. Epidemiological data are uncertain, 
but estimates converge on a prevalence around 0.4-1.0% (147, 148). There are no 
specific tests that will confirm CFS. It is a clinical diagnosis based on thorough 
investigation to exclude other conditions that can explain the fatigue. Several 
definitions have been proposed for the diagnosis and although they include many of 
the same criteria they differ to some extent in duration and number of required 
symptoms (149-151). Presence of persisting severe fatigue of new onset is mandatory 
in all definitions, and in addition there should be a number of other symptoms, for 
instance sleep disturbances, muscle or joint pain, headaches, cognitive dysfunction, 
sore throat or painful lymph nodes.  
Risk factors for CFS are often divided into predisposing, precipitating and 
perpetuating factors(147). Neuroticism and introversion are personality characteristics 
that have been linked to increased vulnerability to CFS. Around 75% of patients are 
women, but the reason for this gender difference is not clear(147). 
A majority of patients with CFS can relate onset to some sort of infection(152). 
Studies have shown that several infections can trigger the condition, including 
Epstein-Barr virus, parvovirus B19, enteroviruses and Coxiella Burnetti(148). 
Adverse life events may also trigger CFS. Case-control studies have shown a higher 
rate of such events among CFS patients in the period prior to onset(153, 154).  
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Factors that may influence the course and prognosis in CFS can be divided into two 
main groups. Patients own ideas about the condition and their level of function, their 
sense of control over symptoms and how they relate to physical activity are linked to 
degree of fatigue. Interactions with others, such as partner, family and health 
personnel, also play a role as this will influence perception and behaviour(147). 
Treatment studies support that these factors are important as both cognitive 
behavioural therapy (CBT) and graded exercise therapy (GET) are found to be 
beneficial(155, 156).  
Fatigue will change over time, as observed in patients with CFS. A systematic review 
concluded that 40% of patients improved over time and 5% eventually recovered 
fully(157). A more precise account of the time perspective was difficult as the 
duration of symptoms at inclusion and follow-up period varied between studies. 
The degree of perceived fatigue or tiredness will vary along a continuum, with no 
clear cut-off to differentiate a medical condition from a normal situation in a healthy 
individual. The degree of fatigue in CFS should be substantial and lead to profound 
reduction in previous activity-levels. None of the criteria for CFS are based on results 
from questionnaires that measure fatigue. From this follows that epidemiological 
studies utilizing questionnaires to assess fatigue cannot identify cases of CFS or 
“fatigue similar to what is seen in CFS”. Caseness will be based on a set cut-off to 
define “fatigue”, “substantial fatigue” or “chronic fatigue” (CF). The value of these 
studies will depend on using questionnaires that are validated and tested on 
individuals in different populations. 
1.3.3 Medically unexplained physical symptoms 
CFS and IBS belong to a group of conditions labelled “medically unexplained 
physical symptoms” (MUPS) that also include fibromyalgia and other pain 
syndromes. They share the characteristic that the symptoms are not explained by 
clinical findings or results of laboratory tests. Some investigators argue that these 
should be considered different manifestations of some common pathologic 
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mechanism(158). Opposed to this is the view that these conditions are not similar and 
are better viewed as distinct entities(158). IBS, CFS and other syndromes are most 
often investigated separately, but when studied together reviews have concluded that 
overlap in prevalence is substantial (159, 160). On the other hand, a prospective study 
on patients with Campylobacter gastroenteritis and mononucleosis found that the two 
infections predisposed to different postinfectious conditions; gastroenteritis to IBS 
and mononucleosis to CF/CFS(161). 
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2. Aims of present study. 
The outbreak in Bergen was the starting point for several research projects on 
different aspects of giardiasis. The aim of the present thesis was to investigate the 
course of giardiasis and its consequences following a large outbreak in a non-endemic 
area. 
In the first weeks after the contamination of the water reservoir was acknowledged 
the aim was to describe the outbreak as it unfolded in two general practice clinics in 
the affected part of the city. When we during clinical practice experienced that a 
substantial number of patients returned to the physician’s office with recurring 
symptoms we extended the project. We followed the patient histories for four months 
in the medical records, and then investigated the presence of persisting symptoms six 
and twelve months after the outbreak.  
Three years after the outbreak we studied another and larger group of patients. The 
aim of this study was to estimate the prevalence and relative risk of IBS and CF in the 
cohort who had giardiasis verified by detection of Giardia in stool samples during the 
outbreak. 
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3. Materials and methods 
3.1 Setting 
3.1.1 Outline of the outbreak in Bergen in the autumn of 2004. 
In 2004 there was a striking increase in the number of diarrhea cases during 
September and October. It was the subject of talk in town, and it was evident at the 
GPs’ offices (figure 2). A noticeable feature that caused concern was the duration; 
usually people would get over a bout of gastroenteritis in a few days, but this time the 
symptoms lasted much longer. Still, it took several weeks before the cause of disease 
was found(162), as physicians were unfamiliar with the clinical picture and 
investigations for detection of Giardia were not performed routinely. The conclusion 
after the outbreak was that there was no uniform diagnostic approach, but that 
different clues or coincidences had led to diagnoses and gradual accumulation of 
identified cases(163).  
 
Figure 2. Number of patients diagnosed with infectious gastroenteritis per week at the 
general practice clinic “Kalfaret legesenter” during the autumn of 2003 and 2004. 
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Both an internal(164) and an external(165) evaluation committee have investigated 
the outbreak. On October 29th the municipal health officer was alerted by the local 
laboratory because in four weeks had identified Giardia cysts in stool samples from 
27 persons who had not been abroad, more than the total number of positive samples 
that would normally be registered through a whole year. A task group was formed on 
the following weekday, November 1st, and information about the outbreak was 
conveyed to the public. The ensuing reaction showed that many of Bergen’s 
inhabitants were affected, and a steep increase in the number of diagnosed cases 
followed. Most new cases were registered in November and in the beginning of 
December, but a few cases linked to the outbreak would be identified each week until 
spring(165).  
A specific investigation into the waterworks and the quality of the drinking water in 
Bergen concluded that Giardia had entered the reservoir “Svartediket” through 
malfunctioning sewers in the surrounding area. Heavy rain fall in the end of August 
was considered the triggering factor, and the drinking water was probably 
contaminated for several weeks (Figure 3)(166).  
 
Svartediket and the central parts of Bergen. (Photo: K-A Wensaas) 
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Figure 3. Possible development of the outbreak week by week in the autumn of 2004. 
Giardia contamination and Giardia in water are estimates. (Used by permission from 
Rådgivende Biologer(166).) 
 
Giardia was the subject of much local attention for a long time after the outbreak. The 
municipality posted regular updates on its web-page, and there were several articles in 
the two major newspapers in the city (Bergens Tidende and Bergensavisen). There 
was a lot of focus on patients not recovering after the infection, and on the 
responsibilities of the municipality as supplier of water to the inhabitants. In April 
2005 the Municipality of Bergen claimed full responsibility for the outbreak and 
decided to give compensation for any verified economical loss to those affected, 
including students’ loss of future income due to delayed completion of exams. Table 
2 shows how the dates for profiled articles in the media related to key dates in this 
project.  
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Table 2. Timetable showing media coverage and development of Giardia-projects. 
Date News-story Research projects 
November 2nd 
2004 
Outbreak of giardiasis detected  
January 11th 2005 Treatment options for resistant 
giardiasis 
 
February 28th 2005 
 
 Registration ended for 
paper I 
April 4th 2005 Municipality claim responsibility, 
will offer compensation. 
 
May 1st 2005  First questionnaire (six 
months) mailed for paper II  
June 6th 2005 Mother of two died after Giardia-
infection 
 
September 24th 
2005 
Doctors uncertain about the 
management of chronic giardiasis 
 
November 1st 2005  Second questionnaire (12 
months) mailed for paper II 
Mars 2nd 2006 
 
Hundreds still sick from giardiasis  
June 10th 2006 Several Giardia-victims claim 
millions of kroner 
 
March 3rd 2007 12 persons still sick after Giardia-
infection 
 
August 5th 2007 Giardia-victims feel they have 
been forgotten 
 
November 1st 2007  Questionnaire mailed for 
paper III 
 
3.1.2 The registered patient list system 
Norway has a registered patient list system for general practice, where every citizen 
can choose to be on the patient list of one specified GP. As of December 31st 2008 
99.6% of the Norwegian population of 4.8 million was part of this system(167). 
Patients are supposed to seek their GP for all first-time contacts with the health 
services, regarding both acute and chronic illness. 
In addition, there are emergency wards open to the public day and night outside 
regular opening hours. During the Giardia outbreak the municipal emergency ward in 
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Bergen registered an increased number of patients with gastroenteritis and 
giardiasis(168). 
3.2 Design 
The outbreak of giardiasis is Bergen constituted a defined and unexpected change in 
the environment and can be considered a “natural experiment”. This gives better 
control of time order as the Giardia-infection preceded the conditions that are 
investigated. Still it was not an experiment in the sense that it was possible to assign 
individuals to the exposure, as defined by contaminated water, infection or clinical 
disease. The design is therefore observational with its problems of bias and 
confounding.  In addition, there is limited control over who was actually exposed, as 
discussed elsewhere in this thesis. 
In the study on patients from general practice (Papers I and II) participants were 
identified and data were collected retrospectively from the medical records, but the 
information was registered prospectively as part of regular clinical work. The follow-
up 6 and 12 months after the outbreak were done prospectively. 
The patients with verified giardiasis during the outbreak (Paper III) were identified 
retrospectively from the records at the parasitology laboratory at the hospital. They 
constitute a historic cohort that has been followed prospectively after the outbreak. 
3.3 Participants 
3.3.1 Patients with giardiasis 
The participants who were sick with giardiasis and investigated in the studies for this 
thesis constitute two different groups, representing two different patient populations. 
The two groups partly overlap. 
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Papers I and II are based on data from 119 patients contacting two general practice 
clinics located in the area supplied with water from the contaminated reservoir 
(Figure 4). The patients were identified by a structured and targeted search in the 
patient records at the clinics, and included based on a clinical case definition, with at 
least one of the following criteria: 
• Two or more of the following symptoms for more than one week: diarrhoea, 
nausea, distension, abdominal pain, foul-smelling flatulence/belching. 
• Positive faecal test for Giardia lamblia (microscopy and/or antigen detection). 
• The responsible doctor stating that the patient has giardiasis, either in the text 
or by giving the specific diagnosis. 
Figure 4. Patients from general practice included in study of giardiasis. 
Data from a period of six months around the time of the outbreak were recorded, 
starting two months before it was publically known. The patients were then mailed 
questionnaires 6 and 12 months after the outbreak and at six months were also asked 
134 patients fulfilled inclusion 
criteria 
9 declined participation 
6 did not respond 
99 patients included in 12 
months follow-up (paper II) 
118 patients included in six 
months follow-up (paper II) 
119 patients included in study 
based on data from medical 
records (paper I) 
1 declined participation in 
further follow-up 
18 did not respond 
1 declined participation in 
follow-up study 
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to submit stool samplesPaper III is based on self-reported symptoms among patients 
three years after they suffered from acute giardiasis during the outbreak. They were 
identified by detection of Giardia in stool samples collected as part of regular clinical 
practice. 66 of the 119 patients in the first group from general practice had a positive 
faecal test for Giardia lamblia, and were thus included in this study as well. The 
samples were analysed at the parasitology laboratory at Haukeland University 
Hospital, the only one of its kind serving the Bergen area. On behalf of the research 
group the laboratory mailed a questionnaire to all patients registered with a positive 
test (Figure 5). 
Figure 5. Participants in a study of self-reported symptoms three years after an 
outbreak of giardiasis. Patients with verified giardiasis during the outbreak, and 
controls matched by age and gender. (Paper III.)  
1225 received 
questionnaire 
817 returned 
questionnaire 
862 returned 
questionnaire 
1128 controls 
included 
817 patients 
included 
14 unknown 
residence 
29 unknown 
residence 
27 unknown 
residence 
2475 received 
questionnaire 
1094 controls, 
group 2 
2504 controls, 
group 1 
1225 patients 
exposed 
1080 received 
questionnaire 
5 giardiasis 
2004 
271 returned 
questionnaire 
1133 controls 
responded 
CONTROLS PATIENTS 
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3.3.2 Diagnostic procedures 
Detection of cysts or trophozoites in stool samples establishes that there is an 
infection with Giardia. Since asymptomatic infection occurs there should also be 
clinical symptoms present in order to diagnose giardiasis, the clinical disease. 
Giardia is commonly demonstrated by two available methods, microscopy and 
antigen detection. Since shedding of cysts is inconsistent there is a risk that diagnosis 
is missed if only one single sample is analyzed. It is therefore recommended that 
regular investigation should include three stool samples from three different days in 
order to improve sensitivity(30). 
When the prevalence of giardiasis is increased, for instance during an outbreak, the 
probability of giardiasis will be higher when a person has symptoms of gastroenteritis. 
In this setting the clinical presentation may be considered to be diagnostic, and neither 
the patient nor the physician would see any added benefit in submitting stool samples 
for analysis.  
The epidemiologist would be interested in complete data on both clinical symptoms 
and stool examination, but in an outbreak situation this goal will seldom be reached, 
especially when many people are affected. For instance, for a period after the 
outbreak was known the municipal health officer requested that physicians did not 
submit stool samples in obvious cases as the capacity at the laboratory was exceeded.  
Registration of symptoms may also be less adequate than expected for research when 
the diagnosis seemed sufficiently clear to warrant treatment.  
3.3.3 Control group 
In the study on which Paper III is based we included a control group. Three main 
issues had to be resolved before the group could be selected. First, we had to define 
which criteria the individuals in the group should meet. We knew that among those 
with verified giardiasis there were more women than men, and nearly 50% were in the 
age group 20 – 29 years(162). In order to balance this we matched the controls by age 
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and gender. The second issue was to decide which population the controls should be 
drawn from. We wanted the controls to differ as little as possible from those exposed, 
and were concerned about the risk of uncontrollable confounders if the sample was 
drawn from a population in another city in Norway, for instance Oslo or Trondheim. 
We ended up recruiting controls from the general population in Bergen, and were 
aware that some of the controls could have been exposed to Giardia and also infected. 
We considered the risk of such misclassification to be acceptable as controls were 
sampled from the whole of Bergen, and those who reported giardiasis during the 
outbreak were excluded. Third, we had to decide on the number of controls. Based on 
the results from a population based study in Norway(169) we assumed the prevalence 
for chronic fatigue to be 0.11 among the exposed, and a statistician performed a 
calculation of statistical power using the software East4. When introducing a 2:1 
matched control group of 2,500 individuals we would identify a difference in 
prevalence of 0.04 between the groups at the 95% power level (two-sided).  We 
expected the actual difference to be larger, but since we could not meet all the 
requirements in the model (the designed model is a randomized trial) and we wanted 
to compensate for potential loss of power after adjusting for other variables in the 
analyses we concluded that this would be an appropriate sample size.  
According to this, Statistics Norway mailed the questionnaire to a group of 2504 
control persons matched by age and gender and drawn from the general population in 
Bergen. Of these, 862 responded (34.4%). In an effort to reduce possible bias caused 
by this low response rate we decided to expand the control group by adding two more 
controls for each exposed individual when none of the first two controls had 
responded. As a result the questionnaire was mailed to 1,094 additional controls six 
months later (Figure 5). 
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3.4 Variables  
The variables and research questions were developed based on observations by 
members of the research group during their clinical work as physicians, and on the 
findings in the studies as the projects evolved. Prior to the outbreak in 2004 health 
services in Bergen had limited experience with giardiasis, and very little was 
published in the literature about the possible long-term consequences following the 
infection.  
3.4.1 Outcome variables 
Gastrointestinal symptoms and functional gastrointestinal disorders. 
In Paper I we describe how a proportion of the patients contacted their GP on several 
occasions because the complaints elicited by the infection persisted in spite of 
treatment. We did not have a clear understanding of the extent of the problem or how 
to interpret what we observed, other than that the symptoms resembled those of acute 
giardiasis. In the questionnaires mailed to the patients 6 and 12 months after the 
outbreak we simply asked whether they still had specific gastrointestinal symptoms 
appearing after the acute infection (Appendices).  
We found that many patients had persisting symptoms even beyond eradication of the 
parasite, and that many of them stopped seeing the health services. This made us 
wonder if a substantial part of all patients in Bergen who got sick during the outbreak 
might have persisting symptoms without our awareness. To investigate this we 
addressed another patient population, everybody who had Giardia detected in a stool 
sample submitted as part of clinical investigation during the outbreak. They received 
similar questions on the presence of specific symptoms two years after the outbreak, 
and it turned out that a 38% reported persisting gastrointestinal symptoms(170). It 
was difficult to interpret the result since we didn’t know what a population without 
previous giardiasis would report, and comparison with other studies suffered since the 
questions were not the same. As a result, when we did a follow-up study one year 
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later (Paper III) we included a control group and we decided to use a questionnaire 
that was accepted as a more valid tool to measure and classify gastrointestinal 
symptoms in the absence of pathological findings. Our main focus was on irritable 
bowel syndrome (IBS), and we designed a questionnaire based on Rome criteria 
(Appendix). When we planned our study the latest Rome III criteria had just been 
published(171). We decided to follow the new criteria; the alternative would have 
been to use Rome II criteria which had been the standard up to that point. There are 
differences between Rome II and Rome III criteria for IBS (Table 3) and it is not clear 
which will most accurately identify the “true” condition. Later studies have shown 
that Rome III criteria will give a higher prevalence of IBS compared to Rome II 
criteria(172-174). 
As it is difficult to assess the clinical implications of the consensus based diagnosis of 
IBS, we designed two categories of more serious IBS. “Frequent IBS” was defined as 
IBS with pain or discomfort more than one day a week. “Severe IBS” was defined as 
IBS limiting or restricting daily activities at least “often”. 
Table 3. Comparing Rome II and III criteria for irritable bowel syndrome (IBS). 
 Rome II criteria(175) Rome III criteria(125) 
Key feature Abdominal pain or 
discomfort 
Recurrent abdominal pain or 
discomfort 
Duration At least 12 weeks (need not 
be consecutive) in the 
preceding 12 months 
At least 3 days per month in 
the last 3 months, with 
symptom onset at least 6 
months ago 
Additional 
characteristics  
(at least two out of 
three) 
• Relieved with defecation • Improvement with 
defecation 
• Onset associated with a 
change in frequency of 
stool 
• Onset associated with a 
change in frequency of 
stool 
• Onset associated with a 
change in form of stool 
• Onset associated with a 
change in form of stool 
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Fatigue 
When patients did not get well after the Giardia-infection we expected 
gastrointestinal symptoms, and in the clinical setting this is what we looked for. But it 
became evident that fatigue might also be a problem, as several patients 
spontaneously complained of this. As a consequence we addressed this through a 
single question in the study performed two years after the outbreak on the group with 
verified giardiasis, and found a prevalence of 41%(170). We felt it urgent to elucidate 
this finding and include a validated set of questions on fatigue in the follow-up study. 
Several questionnaires are designed to measure fatigue, and we wanted one that had 
been used in similar setting previously. We considered the scale used by Hickie in an 
often cited prospective study on postinfectious fatigue following infection with 
Epstein-Barr virus, Coxiella Burnetti (Q fever) or Ross River virus(176),  but it was 
impossible to elicit which scale had actually been used. The article refers to a 12-item 
“SOMA”-scale, but the reference given discusses a 10-item “SOFA”-scale(177). We 
ended up assessing two scales that have been widely used in different settings; the 
Fatigue Severity Scale (FSS)(178) and the Fatigue Questionnaire (FQ)(179) in its 
revised version(180). Some researchers in the group were familiar with the FSS as it 
had been used in patients with chronic fatigue syndrome in our area. However, we 
landed on the FQ, most importantly because it has been used in a study on fatigue in 
the general population in Norway(169). The FQ has also been widely used to measure 
cancer-related fatigue (CRF)(181), and has been considered a useful tool for assessing 
fatigue in a variety of conditions(182). A later review, from 2009, has questioned 
whether it discriminates cases from non-cases with acceptable sensitivity and 
specificity, and its ability to act as an outcome measure sensitive to change with 
disease progression or treatment. In these respects the FSS is considered to perform 
better(183). 
As with IBS we also designed two categories of more serious fatigue. “Severe 
fatigue” was defined as the combination of chronic fatigue and a total fatigue score of 
23 or more, and “consistent fatigue” as chronic fatigue combined with fatigue present 
at least 75% of the time. 
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The term “fatigue” when used in conversation or as a symptom is not easily defined. 
Even though we use the generally accepted Fatigue Questionnaire we decided to 
elaborate further the aspects of this symptom and included Epworth Sleepiness Scale 
in the questionnaire(184). These data are not yet published. 
3.4.2 Explanatory variables 
Exposure to Giardia 
In the study reported in Paper III we included a control group, and whether the 
participants were exposed to infection with Giardia was a key variable in this study. 
Demographic variables 
Age and gender were recorded for all participants in both studies. The cohort of 
patients with verified giardiasis and their controls were asked about marital status, 
level of education, occupation and whether they were students during the outbreak. 
Variables to grade exposure 
In the group of patients from general practice, data concerning the acute phase of the 
infection (result of stool sample analysis, treatment, and time from symptoms until 
treatment) were obtained from the medical records. At six months after the outbreak 
we asked them how much tap water they drank prior to the outbreak, as a measure of 
exposure to the pathogen. A case-control study performed just after the outbreak was 
acknowledged showed that a daily intake of more than five glasses of tap water was 
associated with giardiasis(162). 
Predisposing or perpetuating factors 
The group of patients from general practice where asked about prior abdominal 
complaints in the questionnaire mailed six months after the outbreak. There was poor 
agreement between the answers to that question and what was documented in the 
medical records during the previous two years. We decided to use the data from the 
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medical records in the analyses, as they were not influenced by recall bias. Since both 
IBS and CFS is associated with several psychosocial factors it would be of interest to 
obtain data on this. Twelve months after the outbreak the patients were asked to 
complete the neuroticism-part of the short scale Eysenck Personality Questionnaire 
(EPQ-N).   
When we designed the questionnaire for the three year follow-up, we were unsure 
about introducing questions on psychosocial factors, like anxiety, depression, 
hypochondriasis, neuroticism or adverse life events. We feared that some patients 
would find the questions irrelevant and that introducing them could reduce the 
response rate, even if the response rate among those who received the EPQ-N was 
81% (95/118). Another aspect was that the questionnaire should not be too extensive, 
and the one prepared for the cohort with verified giardiasis (Paper III) already was six 
pages. As a result we decided not to introduce these variables in the questionnaire.  
3.5 Analyses and statistical methods 
In Papers I and II chi²-test or Fischer’s exact test was used to test differences between 
proportions, and Student’s T-test to test differences for continuous variables. In Paper 
II relative risks (RR) were given for categorical variables and mean differences for 
continuous variables in the secondary analysis, both with 95% confidence intervals 
(CI). All tests were two-sided, and level of statistical significance was set at p<0.05. 
All data in Paper I were analysed in SPSS version 14.0, and in Paper II in SPSS for 
Windows version 15.0.  
In Paper III some of the responders did not complete all parts of the questionnaire. 
Persons with missing data were excluded from the analysis involving that particular 
variable, unless data were still sufficient to unequivocally define the outcome 
according to set criteria. For instance, the diagnosis of IBS requires a positive 
response to two out of three questions in addition to presence of abdominal pain.  If 
response to one of those questions were missing, data would still be sufficient if the 
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response to the other two were either both positive or both negative, but not if one 
was positive and the other one negative. 
Association in 2×k tables was tested by Pearson’s chi²-test, and results reported as RR 
with 95% CI. IBS and chronic fatigue were analysed separately with respect to the 
risk factors and possible interactions using multiple logistic regression producing 
adjusted odds ratios (OR) with 95% CI. Since both outcomes are common, the ORs 
will be higher than the RRs and the difference bigger than when outcomes are rare. 
ORs were therefore converted to RRs and corresponding CIs by the method of Zhang 
an Yu(185) in order to improve clarity and interpretation of results. Other methods are 
also available, and they will to some degree yield different results(186). Effect 
modification was tested by the Breslow-Day test for homogeneity of ORs after 
stratification. Confounding was evaluated by use of the Mantel-Haenszel common OR 
and multiple logistic regression analyses, and variables found to be confounders were 
then controlled for by multiple logistic regression. Means of continuous variables 
were compared between groups using Gosset’s unpaired t-test. Internal consistency of 
the FQ was tested by calculating Cronbach’s alpha for all items. Level of statistical 
significance was set at 0.05, and all tests were two-sided. All analyses were done 
using SPSS for Windows version 15.0.  
3.6 Ethics  
All studies in this thesis have been approved by the Regional Committee for Medical 
and Health Research Ethics (projects 060.05, 219.05 and 150.07). All studies are also 
approved by the Ombudsman for Privacy in Research, Norwegian Social Science 
Data Services (projects 12518, 13562 and 17014).  
The studies were all initiated before the new Act on Medical and Health Research 
entered into force in 2009. The purpose of the new act is to improve and simplify the 
regulations in the field by collecting all aspects within the framework of a single act, 
and make researchers relate to one organization only for notification and approval of 
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projects. Any research must now obtain advance approval by the Regional committee 
for medical and health research ethics. The committee’s mandate is to conduct an 
ethical evaluation of the project and to examine that it is in accordance with current 
laws and regulations. 
We have felt an ethical obligation towards the participants in the projects and the 
community both to secure the integrity of the individuals and to maximize the quality 
of the research. We highly appreciate the effort the participants have made by 
supplying the information needed for the studies, and therefore feel it urgent to 
complete the work made possible by their contributions. 
All included individuals have given written consent to participate, for those less than 
18 years old consent was given by a guardian. Non-responders where reminded once 
and requested to participate. The data for Papers I and II will be held for 10 years, for 
Paper III for 30 years. 
The group of patients from general practice were requested to submit stool samples 
six months after the outbreak. All who complied received a written notification of the 
result with instructions on further measures to be taken if the sample was positive for 
Giardia.  
As the projects evolved we found that a substantial proportion of the patients who 
suffered from acute giardiasis in 2004 reported long term complications. This was 
something we had not foreseen. To facilitate further research into mechanisms and 
associations we asked the participants in the study three years after the outbreak 
(Paper III) for consent to link data in the current study with information in health 
registries. 
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4. Summary of results 
4.1 Paper I 
Prevalence of recurring symptoms after infection with Giardia 
lamblia in a non-endemic area.  
In this study we described the course of giardiasis as it was recorded in the patients’ 
medical records, with special attention to prolonged disease and recurring symptoms.  
From the population of 7,100 inhabitants assigned to two general practice clinics 
located in the outbreak area we identified 134 patients who met the criteria for a 
clinical case definition of giardiasis. Of these, 119 gave consent to take part in the 
study. We retrospectively registered data entered into the patients’ medical records 
during the outbreak and up to February 28th 2005, four months after the outbreak was 
publically acknowledged. We also registered any information on gastrointestinal 
complaints in the period two years prior to the outbreak. 
There were more women among the patients (69.3%), and the majority was between 
20 and 39 years of age (51.4%). A positive test for Giardia lamblia was registered for 
55% (66/119) of the patients. Eighty nine (75%) were treated with metronidazole. 
After initial treatment 36% (32/89) returned to their doctor because symptoms 
recurred. Compared to those not returning a significantly higher proportion of this 
group had seen their GP for other GI-complaints in the previous two years (8 of 32 vs. 
3 of 54, p=0.009). A second prescription for metronidazole was given to 28% (25/89) 
of the patients, and most often both the daily dose and the duration were increased. 
After the second treatment 16% (14/89) returned once more, and 11% (10/89) were 
treated a third time. Five patients (6%) not getting well after the third treatment were 
referred to the hospital’s outpatient clinic for further investigations and follow-up. 
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Conclusion: A strict laboratory based diagnosis would have missed a substantial part 
of patients with clinical giardiasis during the outbreak. One third of the patients 
experienced recurring symptoms after treatment, and there was an association 
between previous gastrointestinal complaints and recurrent symptoms.  
4.2 Paper II 
Post-infectious gastrointestinal symptoms after acute Giardiasis. A 
1-year follow up in general practice  
The aim of this study was to investigate the presence of gastrointestinal complaints 
and persistent infection among Giardia-patients in a one year period after the initial 
infection.  
From the study population described in Paper I, 118 patients gave consent to take part 
in a follow-up study, and returned a questionnaire delivered by mail six months after 
the outbreak. They were also requested to submit stool samples. A second 
questionnaire mailed 12 months after the outbreak was returned by 99 patients (84%). 
Eighty two of the patients (69%) submitted stool samples six months after the 
outbreak. Giardia lamblia was detected in samples from three patients, all of whom 
were already referred to the out-patient clinic at the hospital and followed up. In the 
questionnaires returned after six months 37% (44/118) of the patients reported 
gastrointestinal symptoms related to their Giardia-infection. This proportion went 
down to 19% (19/99) after 12 months. The reported water intake prior to the outbreak 
was significantly higher in patients with persistent symptoms, but there was no 
association with gender or neuroticism. 
Conclusion: Persistent gastrointestinal symptoms are common complications after 
giardiasis in a population most likely previously unexposed to Giardia lamblia. This 
study shows an attenuation of symptoms with time. 
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4.3 Paper III 
Irritable bowel syndrome and chronic fatigue three years after 
acute giardiasis: historic cohort study  
The aim of this study was to estimate the relative risk of irritable bowel syndrome 
(IBS) and chronic fatigue three years after acute giardiasis. Data were collected by a 
questionnaire mailed to all 1252 patients with giardiasis verified by detection of cysts 
in stool samples, and to a matched control group of 3598 individuals without previous 
infection. The response rates were 65.3% (817 of 1252) among the exposed and 
31.5% (1133 of 3598) among controls. 
The prevalence of IBS in the group with previous giardiasis was 46.1% (355/770) 
compared to 14.0% (155/1105) in the control group, and the adjusted relative risk was 
3.4 (95% CI 2.9 to 3.8). Chronic fatigue was reported by 46.1% (366/794) of the 
exposed and 12.0% (134/1118) of the controls, the adjusted relative risk was 4.0 (95% 
CI 3.5 to 4.5). IBS and chronic fatigue were associated and the relative risk for the 
exposed group of having a combination of the two outcomes was 6.8 (95% CI 5.3 to 
8.5). The relative risk was also increased for having just one of the two syndromes 
only, 1.8 for IBS (95% CI 1.4 to 2.3) and 2.2 for chronic fatigue (95% CI 1.7 to 2.8). 
The RRs of the secondary outcomes “severe” or “frequent” IBS were 5.1 (95% CI 3.6 
to 7.2) and 6.2 (95% CI 4.5 to 8.3), respectively, and for the secondary outcomes, 
“severe” and “consistent” chronic fatigue, the RRs were 7.4 (95% CI 4.9 to 10.9) and 
3.6 (95% CI 2.6 to 4.7). 
Conclusions: Infection with Giardia lamblia in a non-endemic area was associated 
with a high prevalence of irritable bowel syndrome and chronic fatigue three years 
after acute illness, and the risk was significantly higher than in the control group. This 
indicates that the potential consequences of giardiasis are more serious than 
previously known.  
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5. Discussion 
The main finding in this thesis is that acute giardiasis is associated with long-term 
postinfectious gastrointestinal disorders and chronic fatigue. This is based on 
observations during the outbreak and 6 months, one year and three years afterwards. 
5.1 Strengths and weaknesses 
Outbreaks offer good opportunities to investigate clinical aspects of infectious 
diseases because exposure will be quite clearly defined and the number of patients 
will often be large. However, there are several limitations inherent in this kind of 
research and even though they are hard or even impossible to avoid they should be 
addressed. 
5.1.1 Research on outbreaks of disease 
Large clinical research projects based on outbreaks of infection are rare. Outbreaks 
will often hit at random and in places far from the expertise on that particular 
infection. For professionals involved, focus will be on public health issues and patient 
care. The main tasks will be to determine the source of the outbreak, find the etiologic 
agent and determine the number of affected patients. This is necessary in order to 
close the routes of transmission and give proper treatment to those with disease. As a 
result, most articles describe the issues mentioned above, since this information would 
have been recorded as part of the regular surveillance of the outbreak. Further 
research is often limited by restricted resources and limited time to set up a research 
protocol, apply for necessary approvals and raise the funds needed. 
A major strength of this project is that we responded fast, established a research group 
and managed to investigate several aspects of the outbreak in Bergen. We have 
described and analysed the clinical manifestations during the acute phase, as they 
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were recorded by GPs in real time. The data were collected after the outbreak 
subsided, but we found that the quality of the registration was good, for instance did 
all GPs consistently record key symptoms and duration of illness for all patients 
identified. We have also followed patients and registered symptoms several times 
after the acute disease. The quality of the joint scientific effort in Bergen is enhanced 
by a continuous collaboration between researchers from both primary and secondary 
care.  
5.1.2 Lack of baseline data from the time prior to the outbreak. 
Valuable background data about patients prior to outbreaks will often be scarce. We 
have some data on the patients from general practice (Paper I), but none that is 
systematically registered. Assessing retrospective information on symptoms or 
characteristics is very difficult, and should be done with great care. In our studies we 
have decided not to focus on these factors and accept the limitations this causes. 
5.1.3 Risk of misclassification 
When describing the overall effect of an outbreak of infectious disease there is always 
an inherent risk of misclassification of patients. This means that a person with disease 
is classified as without disease, or the other way round. When evaluating this risk 
several aspects must be considered: 
- The definition of disease in contrast to asymptomatic infection.  
- The prevalence of the infection, both symptomatic and asymptomatic, in the 
population. 
- The sensitivity and specificity of the diagnostic test. In this setting the word 
“test” includes both analyses in the laboratory and clinical signs and 
investigations. 
 53 
Persons with disease falsely classified as without disease.  
This may result from a diagnostic test being falsely negative, or the test not being 
applied (either because the person didn’t seek health care or because the test was not 
performed). There may be systematic differences between patients falsely classified 
as without disease and those correctly identified.. This can be attributed to both 
different sensitivity and specificity of the test in the groups, to different clinical 
presentation and severity, and to difference in patients’ vulnerability or threshold to 
seek health care. The identified patients, the “true positives”, may be more susceptible 
to infection, to complications or both, compared to the unidentified patients, the “false 
negatives”. 
Persons without disease falsely classified as having disease.  
The diagnostic test might not differentiate between persons with the disease in 
question and other conditions. This pertains to the specificity of the test. Symptoms of 
gastroenteritis may be considered diagnostic of giardiasis during an outbreak, but it is 
possible that in some cases there would be another cause. Laboratory tests may also 
give a positive result even if the pathogen is absent. Another aspect of laboratory tests 
is that they will not differentiate between persons with disease and asymptomatic 
carriers of the pathogen. If clinical information is missing it will be difficult to define 
the population that is being investigated. A person without symptoms who wants an 
investigation because of exposure (for instance high intake of tap water during the 
outbreak) belongs to a different population than a person with severe and typical 
symptoms of giardiasis. The pre-test probability will be different, and the risk of 
getting a false positive result will differ accordingly. Those individuals without the 
disease, but receiving the diagnosis and getting misclassified, the “false positives”, 
will differ from the “true positives” in exposure. They may also differ from the “true 
negatives” in respect to previous health complaints, health care seeking behaviour and 
susceptibility to persisting symptoms. 
When recruiting participants based on health-care seeking behaviour there will be 
reduced control of what the pre-test probability of disease is, since people’s 
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inclination and reason for seeing their doctor will vary. The population in question 
will also differ depending on whether the persons are recruited from primary, 
secondary or tertiary care. It is therefore important to bear in mind which group of 
patients that have been investigated, especially when discussing to what extent the 
results will be valid in other populations. 
5.1.4 Selection bias in relation to identified patients  
Participants were included based on attendance at the GPs office or on the 
investigation of stool samples submitted as part of regular clinical practice. The 
composition of the study groups will therefore be influenced by health-care seeking 
behaviour by individuals. We have tried to include all patients in the defined groups, 
but their identification also relied on the actions or information recorded by the 
physicians. As diagnosis will more readily be made based on typical symptoms, 
patients with few or atypical symptoms might be missed. In a cohort of patients with 
laboratory verified giardiasis the physicians’ decision to ask for stool samples was 
instrumental in defining the patient population. The inclination to do this will most 
certainly vary over time for any one physician, and also more systematically between 
different physicians.  
In the study referred in Paper III we have included patients with giardiasis based on 
detection of Giardia in stool samples. This group might differ from patients with 
giardiasis without positive stool samples, who will either have a negative test result or 
did not submit a sample. The risk of a false negative result may be higher in patients 
with fewer parasites or cysts in the stool, which may also lead to milder disease and a 
lower risk of complications. There may be several reasons why a stool sample was not 
submitted for investigation, some decisions made by the doctor and some by the 
patient. Patients with less symptoms and/or spontaneous recovery may not have 
contacted the health services at all. For patients with more severe and typical 
symptoms of giardiasis during the outbreak physicians would probably prescribe 
treatment without waiting for the result of stool analyses. Then stool samples might 
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not be submitted, either because the doctor didn’t find it necessary or because the 
patient didn’t see the benefit. Since treatment failed in some cases this could prompt 
patients with more complicated infection to submit stool samples.  
5.1.5 Selection bias in relation to included patients and controls. 
In the study from general practice, 89% (119/134) of the identified patients were 
included, with response rates of 88% (118/134) after 6 months and 74% (99/134) 
after 12 months. In the study of patients with verified giardiasis the response rate was 
65.3% in the exposed group. These rates are acceptable, and high compared to other 
studies investigating postinfectious complications after bacterial gastroenteritis, based 
on both mailed questionnaires(128) and consultations(133). Still there is a risk of bias, 
but it is difficult to estimate how this would influence the results. Non-responders 
could be recovered patients who felt the questionnaire did not concern them, but also 
include some with severe symptoms and no wish or energy to complete yet another 
questionnaire.  
The low response rate (31.5%) among the controls in the last paper gives reason to be 
aware of possible selection bias in this group. We are to a certain extent reassured by 
the fact that a prevalence of 14% IBS and 12% chronic fatigue is not very different 
from what has been found in population based studies in Norway(169, 187). 
Nevertheless, a higher response rate would be desirable. We tried to address this by 
expanding the control group after we found that the initial response rate was only 
34.4%, but we ended up with just 24.8% of the additional controls responding. What 
we gained in number of cases and better control of random statistical error we may 
have lost in reduced response rate and greater risk of systematic error.   
5.1.6 Recall bias and information bias. 
The answer to any question relating to the past may be imprecise or incorrect. In the 
study from general practice on which Paper II is based we asked the patients whether 
they had abdominal problems or symptoms prior to the outbreak. The answers did not 
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correlate well with the information in the medical records referred in Paper I, and 
therefore were difficult to interpret. The main topic of interest in the study was 
persisting symptoms after giardiasis, and we asked the participants about persisting 
symptoms that were new after they fell sick with giardiasis. Although this pertained to 
the current situation, there was also an aspect of recall. They may be inclined to relate 
chronic recurring symptoms to the Giardia-infection and give a positive response 
suggesting a relationship where in fact it may be weak.  
In the larger cohort of patients with verified giardiasis and their controls we asked 
about current symptoms. The answers would not be dependent on memory, but there 
might still be some information bias. There is a possibility that those having suffered 
acute giardiasis would be more aware of symptoms and more likely to find them 
abnormal than the controls, and thus more often report complaints.  
5.2 The scale of the outbreak of giardiasis in Bergen 2004 
We know that at least 48,000 individuals were potentially exposed to Giardia cysts in 
the drinking water. This is the number of registered subscribers receiving water from 
the contaminated reservoir(162). Many people from outside the area were also 
exposed as they would visit shopping areas, offices, schools and universities in the 
central part of the city. Intake of tap water, drinking more than 5 glasses daily, was 
associated with an increased risk of giardiasis(162), but we don’t know the number of 
people with an intake of tap water sufficient for getting the infection.  
The exact number of affected patients is unknown, as there were no precise records of 
all giardiasis cases. It has been suggested that 5 - 6,000 persons might have been 
infected, with varying degree of illness(165). This estimate is most unsure, as there 
was no environmental testing of persons receiving water from Svartediket during the 
outbreak. In view of the high number of people exposed this could be considered a 
conservative estimate. 
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The parasitology laboratory at Haukeland University Hospital, the only one of its kind 
serving the Bergen area, detected Giardia in stool samples from 1,253 persons 
assumed to have been infected during the outbreak. The samples were all submitted as 
part of regular clinical work.  
Twice as many were probably treated for giardiasis. A review of prescriptions for 
metronidazole at pharmacies in Bergen concluded that an excess of 2,500 persons 
were treated in the months following the outbreak, compared to the period 
before(162). In paper I of this thesis we report that 55% of patients with clinical signs 
of giardiasis had the diagnosis verified by a positive stool sample. A review of 
medical records at Bergen Accident and Emergency Department revealed the same 
trend; 420 patients had records were the name “Giardia” was entered and for 200 of 
them (48%) a positive stool sample was registered(168). This supports that the 
number of affected individuals was at least twice the number of infected patients 
registered at the laboratory, probably somewhat higher. In our study 89 out of 119 
patients (75%) received treatment by their GP. Some of the remaining patients may 
have been given metronidazole elsewhere without this being registered in the medical 
records, but it is unlikely that this is the case for all of them. This illustrates that a 
proportion with symptomatic giardiasis was not treated. One reason could be 
spontaneous recovery as diagnosis was delayed.  
During the outbreak it was feared that a substantial number of asymptomatic carriers 
might constitute a reservoir for subsequent outbreaks in the years to come. 
Fortunately, history has so far not confirmed this concern. And further, one year after 
the outbreak the prevalence of Giardia in preschool children living in the exposed 
area was low (1.7%), and small children are thus unlikely to be a source of continued 
transmission(188). 
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Table 4. Number of persons affected during the outbreak of giardiasis in 2004. 
Number of 
persons affected Characteristic of group 
48,000 Registered receivers of water from contaminated source (“exposed”)(162) 
5,000 Unverified estimate of persons with infection (“infected”) 
2,500 Persons treated with metronidazole (“clinical disease”)(162) 
1,250 Persons with Giardia in stool samples (“verified giardiasis”)(170) 
 
5.3 The clinical consequences of giardiasis  
Why does a substantial proportion of the patients with acute giardiasis in 2004 report 
long lasting symptoms? 
This thesis, together with other studies after the outbreak, sheds light on the long term 
effects of giardiasis in a previously unexposed population.  
Before 2004 large waterborne outbreaks of giardiasis had never before been 
registered in Norway. Neither the Water and Sewerage Works of Bergen nor the 
health services anticipated that Giardia could strike here. As a result of the delayed 
detection many patients had symptoms for several weeks before treatment. In the 
group of patients from general practice the mean interval from onset of disease was 
5.7 weeks (Paper I). Once diagnosis was made, however, there was good reason to 
believe that the situation would be resolved, as metronidazole treatment was readily 
available. The literature gave no indication that the infection would cause prolonged 
problems, with the exception of possible treatment failure in a small proportion of 
cases. Recurring symptoms were therefore perceived as persisting infection, and new 
courses of metronidazole were prescribed. A few metronidazole resistant cases would 
be referred to the hospital’s outpatient clinic, and all known patients would eventually 
have the parasite eradicated(47).  
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When symptoms continued this was something the patients experienced in contrast to 
the physicians’ expectations. We found that already in the first period after the acute 
infection the proportion of patients with recurring or persisting symptoms at the GPs 
offices was higher than expected (paper I). Six months later 37% of the patients still 
reported gastrointestinal symptoms that they did not have prior to the infection, after 
12 months this proportion was 19% (Paper II). 
At the hospital’s outpatient clinic they found that among 124 patients admitted 
between January 2005 and March 2006 with persisting symptoms both microscopy 
and antigen test for Giardia were negative in 84(42). Many of these patients also 
complained of fatigue and some were referred for further investigation (Kurt 
Hanevik, personal communication). 
The first investigation on a larger cohort was done two years after the outbreak. All 
patients registered with a positive faecal test for Giardia received a questionnaire by 
mail, and 1017 of 1262 responded (81%). The questions were not standardised to set 
specific diagnoses, but 38% (389/1017) reported abdominal symptoms elicited by the 
infection, and 41% (419/1017) reported having problems with tiredness. 
Three years after the outbreak the same cohort and a matched control group received 
a new questionnaire designed to diagnose IBS and chronic fatigue. The prevalence of 
IBS was 46% in the Giardia-group, compared to 14% in the control group, and the 
prevalence of chronic fatigue was 46% and 12%, respectively. The corresponding 
relative risks were 3.4 and 4.0 (Paper III). In the Giardia-group there was also a 
higher prevalence of the secondary outcomes “severe” and “frequent” IBS, and also 
“severe” and “consistent” chronic fatigue, with RRs in the range 3.6 – 7.4. This 
suggests that the results represent clinically significant symptoms and possible loss of 
function. 
The studies in this thesis show that patients consistently had persisting symptoms after 
giardiasis from the time the acute infection hit and up to three years after.  We have 
shown that 36% (32/89) of patients treated for giardiasis in general practice 
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experienced recurring symptoms (Paper I). In some this was caused by treatment 
failure and persisting infection, but even after eradication of the parasite a substantial 
proportion experienced prolonged abdominal symptoms; 37% (44/118) after 6 months 
and 19% (19/99) after 12 months (Paper II). A study that is not part of this thesis 
found that in a cohort of patients with verified giardiasis 36% reported abdominal 
symptoms and 41% tiredness two years after the outbreak(170). We have 
demonstrated a high relative risk of clinically significant IBS and chronic fatigue after 
three years in the same cohort (Paper III). The prevalence of the outcomes in the 
papers differ, and is highest after three years. These numbers cannot be directly 
related to each other since the populations and settings are different, the samples sizes 
vary and the questionnaires were not the same. Differences in response rates could 
also play a role. All these factors and the possible biases discussed above illustrates 
that the accuracy of the numbers to some extent will be uncertain. But the observed 
associations between acute giardiasis and prolonged postinfectious conditions are so 
strong that the conclusions are considered to be valid. 
5.4 Interpretation 
The theory that the symptoms were explained by chronic infection not identified by 
analysis of stool samples was not confirmed. At the university hospital an extended 
antibiotic regime was given to 25 patients with persisting symptoms and negative 
stool analysis. They received treatment with either albendazole/metronidazole or 
tetracycline/folate. Initially four patients reported substantial improvement, but 
symptoms later recurred in all four. One year later 24 still reported abdominal 
symptoms(189).  
The outbreak in Bergen was caused by Giardia assemblage B(190). There are 
indications that different strains differ in their ability to produce disease in man(29, 
191), but there are no conclusive data on the importance of different assemblages.  
 61 
The mechanisms for prolonged symptoms and loss of function are unclear. In 
medically unexplained physical symptoms possible important factors have been 
divided into three groups; premorbid disposition or vulnerability, factors that trigger 
the condition (for instance an infection) and factors that sustain it. 
We have little data on premorbid vulnerability. In Paper I we found that among the 
patients returning to their GP with recurring symptoms a significantly higher 
proportion had seen a physician for abdominal complaints the previous two years. 
This was an objective measure since the data were extracted from the medical 
records. However, the number of patients was low. The larger cohort was asked two 
years after the outbreak about abdominal problems prior to their Giardia-infection. 
There was no association between the response to that question and current abdominal 
symptoms(192).  
We were reluctant to retrospectively introduce questions on psychological factors and 
adverse life events in mailed questionnaires. We feared that participants would find 
these issues of limited relevance, and possibly lead to lower response rate. The results 
would also be vulnerable to recall bias as discussed above. However, in paper II we 
did include the neuroticism-part of the short-scale Eysenck Personality Questionnaire 
(EPQ-N) at 12 months. This consists of 12 questions to be answered by “yes” or “no”, 
giving a total score between 0 and 12(193). Of the 118 persons invited to participate, 
99 returned the questionnaire and 95 completed the EPQ-N (80.5% response rate). 
The interpretation of the results will be restricted by the cross-sectional design and the 
low number of patients, but we did not find any correlation between EPQ-N score and 
persistent symptoms. 
Acute giardiasis is the triggering factor in this group of patients, but it is intriguing 
that this non-invasive infection of the small intestine causes persisting systemic 
symptoms and impaired function of the large bowel.  
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Duodenal inflammation persisted for a period after successful treatment in some 
patients referred to the hospital(42), and in another group some degree of visceral 
hypersensitivity was demonstrated(194).  
Lactose intolerance has been suggested as a cause of lasting symptoms, but this has 
not been backed by research. Reduced lactase activity during infection has been 
shown in experimental studies of giardiasis in gerbils(195), and also in Giardia-
patients(196). However, lactose intolerance does not seem to play a role in the 
development of postinfectious IBS after bacterial gastroenteritis(197), nor does 
subjective milk intolerance predict lactose intolerance in IBS patients(198). In Paper 
III we found no correlations to support that lactose intolerance is the mechanism for 
post-giardiasis IBS. Also, lactose intolerance could hardly explain the fatigue. And 
finally, if this was the explanation, patients would be likely to experience 
exacerbation of symptoms related to intake and avoid milk. The symptoms should 
therefore subside. 
The mechanisms of parasite pathogenicity and the host response in giardiasis are 
largely unknown. During the acute infection there are various degrees of 
inflammation with villous abnormalities, epithelial dysfunction and disruption of tight 
junctions, but in many patients with symptomatic giardiasis there is no detectable 
microscopic changes. Both mast cells and T-cells play a role in the immune response, 
as do B-cells which produce IgA and IgG anti-Giardia antibodies. However, most of 
what is known about disease mechanism is based on studies in animals, and has not 
been confirmed in humans(199). The results of infection are hypersecretion, 
malabsorption and reduced disaccharidase activity causing diarrhoea and other 
gastrointestinal symptoms(200). Fatigue has also been identified as a common feature 
of acute giardiasis(33). This means that a large proportion of patients suffered from 
long term symptoms that resemble those of the acute infection. It is not clear why 
symptoms persist. A broad approach to the pathogenesis is needed, and focus should 
be on both pathogen and host factors. The immune response may be important, in 
particular T-lymphocytes. Their role has been linked to acute giardiasis(199). In 
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postinfectious IBS T-lymphocyte infiltration has been reported(138) and the 
conclusion of a systematic review was a trend towards increased T-cell activity in 
patients with CFS(201). Another approach to the understanding of both IBS and 
chronic fatigue has been to focus on the hypothalamus-pituitary-adrenal axis (HPA 
axis)(202, 203). There is no obvious one-dimensional connection between giardiasis, 
or infections in general, and the HPA axis, but this scope opens for a more multi-
dimensional understanding of the pathogenesis of unexplained somatic disorders, 
including immunological, endocrinological, psychological and even cultural 
influences.   
We have not investigated patient factors that might sustain symptoms, like anxiety, 
depression, hypochondriasis, adverse life events and patients coping ability and 
strategies. 
The municipality of Bergen claimed full responsibility for the outbreak and decided to 
give compensation to those affected. The conclusion was reached in the beginning of 
April 2005, after a period when several patients had voiced their discontent in the 
media and in meetings with politicians. This could possibly lead to aggravation of 
symptoms, both because the dissatisfaction with the authorities could counteract 
health promoting mechanisms and because symptoms could have consequences for 
the claims. On the other hand, having somewhere to place responsibility and blame 
could move focus from what had happened during the outbreak towards future 
improvement and coping. Also the benefit of exaggerating the symptoms would be 
limited as compensation was restricted to any verified economical loss. Although 
these considerations will apply in all outbreaks of disease caused by contamination of 
public water we have not seen this addressed in other studies published after 
waterborne outbreaks. 
Finally, in the effort to contribute with novel findings one should bear in mind the 
possible pitfalls of assumed causality. In order to avoid this several criteria for 
causality have been proposed. The list presented by Bradford Hill in 1965 is still 
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accepted as a valid framework(204). There are nine aspects that should be considered 
before inferring that an association is explained by causation: 
1. Strength. The stronger the association the more likely causation will be, but he 
warns against dismissing causality barely on the grounds of a wearer 
association. 
2.  Consistency. An association observed several times by different observers, in 
different settings and populations, is more likely to be causal. 
3. Specificity. If one factor is associated to a specific disease or other restrictions 
concerning outcome this will be an argument for causality. However, there are 
also good examples of non-specificity, for instance smoking increasing the risk 
of several diseases, and several risk factors increasing the risk of coronary 
heart disease.  
4. Temporality. The cause must precede the effect. 
5. Biological gradient. When possible one should try to find evidence of a dose-
response curve, and if found this suggests causality. 
6. Plausibility. Although dependent on the state of current knowledge a proposed 
causation is more likely if biologically plausible. 
7. Coherence. A theory of causal relationship should be coherent with other 
knowledge of the disease and the potential causal factors.  
8. Experiment. Introducing a causal factor would not be ethically possible, but 
removing the factor could yield support for causality. 
9. Analogy. If similar situations or factors have caused serious effects it could be 
argued that analogy should be deemed sufficient to infer causality, as a 
precautionary principle.  
The criteria relating to specificity or biological gradient are not met. The association 
between acute giardiasis and postinfectious complications is consistent in several 
studies following the outbreak in Bergen, but should be confirmed in other settings 
and populations. Based on studies on postinfectious complications among patients 
suffering from other infections and possible mechanisms, one could argue that 
 65 
causality to some extent is supported by analogy, and maybe also plausibility and 
coherence. The studies in this thesis were based on a “natural experiment” as the 
outbreak happened by accident, and though this design is weaker than a proper 
experiment it should be given consideration in the interpretation of the results. At 
least it suggests that the infection preceded IBS and chronic fatigue. All these 
indications and the strength of the association constitute substantial support for 
causality between acute giardiasis and postinfectious IBS and chronic fatigue. 
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6. Conclusion 
Infection with Giardia lamblia is associated with an increased risk of persisting 
abdominal complaints like IBS and chronic fatigue. This has been shown in studies 
performed in the acute phase of the infection and on patients six months, one year, 
two years and three years after the outbreak. 
The association between acute giardiasis and postinfectious IBS and chronic fatigue is 
strong, and although we have not investigated all possible contributing factors, we 
conclude that it is valid for a previously unexposed population. This shows that the 
potential consequences of giardiasis are more serious than previously known. 
One should be cautious about applying the results from our studies on patients in 
areas where Giardia is endemic. 
There might be important contributing factors to the development and maintenance of 
postinfectious IBS and chronic fatigue, but the studies in this thesis were not designed 
to investigate this. 
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7. Further research 
There are still many unanswered questions about Giardia, giardiasis and 
postinfectious complications. The following topics should be addressed in future 
research: 
We have found a strong association between acute giardiasis and postinfectious IBS 
and fatigue, but the design is observational and the results should be confirmed. In 
case of future outbreaks of giardiasis or other infectious diseases, experienced 
research groups like ours in Bergen, and the one at McMaster University in charge of 
the Walkerton investigations, should be considered important resources. 
In order to improve the understanding of IBS, chronic fatigue and possibly other 
medically unexplained physical symptoms, further research into the mechanisms of 
giardiasis and other infections, as well as the mechanisms of IBS and fatigue should 
be performed. 
The number of chronically affected individuals in Bergen emphasises the need for 
further research on treatment for chronic fatigue and IBS. 
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